Acalabrutinib Still Outperforming in R/R CLL: Three-years Follow-up of ASCEND
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read More
Dissemination (Meeting Coverage)
OS benefit seen in 5-year data on ELEVATE-TN trial in CLL
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read More
Add-on Tiragolumab Doesn’t Improve on Atezolizumab in Extensive Stage Small Cell Lung Cancer
A Late-breaking session at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting,...
Read More
Randomized Trial for High-risk Cutaneous Squamous Cell Carcinoma Patients Treated With Adjuvant Cemiplimab
High-risk patients with cutaneous squamous cell carcinoma (CSCC) have an unmet need with regard to...
Read MoreMost With MS Experience Early-Onset Fatigue
Most individuals with MS reported mild fatigue early in their disease course, at least one-half of whom experienced increasing fatigue over time, according to findings presented at the 2022 Consortium of Multiple Sclerosis...
Read More
Wellness Program Improves Disease Markers & Physical Activity in Patients With MS
Patients with MS who participated in a weekly, structured wellness program demonstrated ongoing,...
Read More
SKYSCRAPER-02: Additional Tiragolumab Does Not Help Patients With Untreated SCLC
Tiragolumab, added to atezolizumab, carboplatin, and etoposide, did not improve the...
Read More
YAP-1: Immunotherapy Efficacy in ES-SCLC Patients
In extensive-stage small-cell lung cancer (ES-SCLC), IMpower133 improved progression-free survival...
Read More
Low-Dose Radiotherapy Plus Atezolizumab & Chemotherapy Benefits ES-SCLC
Researchers conducted the MATCH study to assess the clinical benefits of adding low-dose...
Read More
ES-SCLC: Anti-PD-L1 Blockades With Etoposide & Platinum
According to IMpower133 and CASPIAN, anti-PD-L1 blockades combined with etoposide and platinum...
Read More
Neoadjuvant Immunotherapy for Advanced, Resectable CSCC-HN
Researchers studied neoadjuvant immunotherapy to produce a pathologic response in patients with...
Read More
Usage of Immunotherapy in Merkel Cell Carcinoma
Merkel Cell Carcinoma (MCC) was rare, and aggressive skin cancer became more common as the...
Read More
Treatment Resistant HPV+ Head & Neck Squamous Cell Carcinoma
Cancer’s biological behavior was exceedingly complex, driven by the nonlinear interplay of...
Read More
Age Associated Mutation in Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma was the most frequent type of skin cancer globally. The presence...
Read More
Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
In the United States, almost 1.5 million cutaneous squamous cell cancer (cSCC) are identified...
Read More
CLL: Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil
Researchers previously demonstrated improved efficacy of acalabrutinib (A) obinutuzumab (O) vs. O...
Read More
R/R CLL: Acalabrutinib Vs Rituximab With Idelalisib or Bendamustine
Acalabrutinib (Acala) was a next-generation, highly selective, covalent Bruton tyrosine kinase...
Read More
SEER Program Data: Chronic Lymphocytic Leukemia Patients
Over the last 2 decades, treatment for chronic lymphocytic leukemia (CLL) has evolved...
Read More
Survival Outcomes in Chronic Lymphocytic Leukemia Patients
For a study, researchers sought to see if patients with chronic lymphocytic leukemia (CLL) who...
Read More
Reduced Disease Progression With Ublituximab vs Teriflunomide in MS
Ublituximab is a new monoclonal antibody that targets a specific epitope on the antigen CD20....
Read More